this drug was shown to reduce CAP values independently of a glucose-lowering effect and to improve lipid, glycemic, and hepatic serum parameters [68]
Secondary outcomes The secondary outcomes are as follows: type 2 diabetes, glucose, HbA1c, insulin, lipid profile (LDL-cholesterol, HDL-cholesterol, triglycerides and apolipoprotein B), systolic blood pressure, diastolic blood pressure, and body mass index (BMI), which are well-established risk factors for CVD in clinical practice, or recently identified to be related to CVD in MR, such as apolipoprotein B [30, 31]
(2007) published in Nature results showing that thymosin beta-4 reactivates epicardial progenitor cells in adult mouse hearts
Suitable for: All skin types, professional and retail use
BPC 157